The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.565
Bid: 1.53
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.07 (4.575%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.565
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

Fri, 01st May 2020 11:18

(Alliance News) - The following is a round-up of quarterly, interim or full-year reports by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

InfraStrata PLC - natural gas storage and infrastructure - Pretax loss in six months to January 31 widens to GBP2.9 million from GBP394,627 amid sharp rise in management and administrative expenses to GBP2.8 million. Generates revenue of GBP515,230, versus none last year. Targets break-even at Harland & Wolff Belfast shipyard inside next 12 months.

----------

Flowtech Fluidpower PLC - fluid power components and services - Revenue in 2019 edges 0.3% higher to GBP112.4 million from GBP112.1 million, but pretax profit falls by 32% to GBP4.7 million from GBP6.9 million. Reports GBP1.7 million in depreciation of right-of-use assets, while administrative expenses rise 12% to GBP26.2 million. Decides against final dividend, means full-year payout down 65% to 2.13 pence per share from 6.07p.

----------

Block Energy PLC - exploration and production - Posts a widened pretax loss in 18 months to December 31. Previously changed its year-end date from June 30. Loss totalled USD6.1 million versus USD2.0 million. Generated revenue of USD314,000 versus USD179,000.

----------

Aminex PLC - oil & gas producer - Pretax loss in 2019 narrowed to USD15.2 million from USD48.5 million. Reported exploration impairments of USD10.9 million, down 75%. Revenue fell 42% to USD357,000 from USD617,000.

----------

Emmerson PLC - potash developer - Pretax loss in 2019 narrowed to GBP1.1 million from GBP1.8 million, amid absence of GBP698,000 in reverse acquisition expenses. Has moved to cut down on expenditure amid Covid-19.

----------

Taseko Mines Ltd - copper producer - Says revenue in three months to March 31 down 12% year-on-year to CAD62.1 million, about GBP35.2 million. Copper production up 30% to 32.4 million pounds from 24.9 million pounds.

----------

Panther Metals PLC - minerals explorer - Pretax loss in 2019 widened to GBP749,948 from GBP519,134 due to initial public offering costs of GBP305,134. Says outlook positive amid promising gold market.

----------

Shefa Gems Ltd - exploration and development - Swings to loss of NIS7.9 million, about GBP1.8 million, from NIS6.0 million. Aiming to continue mine planning procedures with the Israeli Lands Authority.

----------

Africa Opportunity Fund Ltd - investor - Net asset value per share at December 31 year-end down 4.9% to USD0.638 from USD0.671. Says performance lagged that of the Lusaka Stock Exchange in 2019.

----------

Marwyn Value Investors Ltd - investor - Reports share price total return of negative 17% compared to FTSE All-Share which gained 19%. Net assets down 29% to GBP105.0 million from GBP147.1 million.

----------

Papillon Holdings PLC - investment vehicle - Pretax loss in 2019 widens to GBP582,000 from GBP397,000. Administrative expenses up 20% to GBP443,000. Says acquisition of 50% stake in Pace Cloud Ltd progressing well.

----------

Golden Rock Global PLC - investment vehicle - Pretax loss in 2019 stretched to GBP393,871 from GBP227,983. Professional fees more than doubled to GBP272,308 during year where it came close to sealing acquisition before target company pulled out.

----------

New Century AIM VCT2 PLC - venture capital trust - 2019 NAV per share inches 2.4% higher to 49.53p from 48.38p, but axes dividend after 3.40p payout in 2018. Says UK general election result boosted certainty but notes volatility from Covid-19.

----------

Conygar Investment Co PLC - investor - Net asset value per share down 0.2% to 177.8 pence in six months to March 31 from 178.2p in September. NAV hurt by GBP1.3 million writedown at Cross Hands retail park in Carmarthenshire, Wales, due to Covid-19.

----------

Pires Investments PLC - investor - Net asset value in year ended October 31 climbs sharply to GBP2.6 million from GBP949,617 in year before. Pretax profit more than doubles to GBP865,510 from GBP322,069.

----------

Cardiff Property PLC - property investor - Ups dividend for six months to March 31 by 4.3% to 4.8 pence per share from 4.6p and NAV per share up 5.4% to 23.03p from 21.84p. Reports property market has uncertain picture due to Covid-19 but says Thames Valley area it operates in has been historically resilient.

----------

Weiss Korea Opportunity Fund Ltd - real estate investment - NAV per share rises 3.7% in 2019 to GBP1.5559 from GBP1.4993. Raises annual dividend by 21% to 4.1195p per share from 3.4155p. Noted that it outperformed the MSCI South Korea Index in 2019.

----------

Sigma Capital Group PLC - residential development - Revenue in 2019 rises 11% to GBP13.9 million from GBP12.5 million, with pretax profit climbing 17% to GBP13.0 million from GBP12.2 million. Holds total payout at 2.0p per share. Says Covid-19 impact difficult to predict. Will change year-end date to September 30 to better reflect season trading patterns.

----------

Highcroft Investments PLC - property investor - Net asset value per share falls 2.7% in 2019 to 1,175p from 1,205p. Slices final dividend by 20% to 27p per share from 33.75p, total payout down 8.6% to 48p from 52.50p. Net property income up 16% to GBP5.7 million and 12% rise in property valuation to GBP86.7 million from GBP77.7 million.

----------

Hemogenyx Pharmaceuticals PLC - cancer therapies - Pretax loss narrows to GBP1.5 million in 2019 from GBP1.6 million. Administrative expenses down 2.5% to GBP1.6 million and company reports other income of GBP213,126, more than double the amount from 2018.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2020 18:25

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

Read more
30 Jun 2020 17:07

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

Read more
26 Jun 2020 14:50

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

Read more
15 Jun 2020 17:54

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
12 May 2020 18:09

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Read more
22 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

Read more
22 Apr 2020 06:55

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Read more
20 Feb 2020 15:15

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Read more
11 Feb 2020 12:00

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Read more
30 Jan 2020 15:47

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Read more
15 Jan 2020 13:23

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Read more
18 Nov 2019 11:51

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Read more
23 Oct 2019 10:43

Hemogenyx signs another deal with unnamed global pharma company

(Sharecast News) - Biopharmaceutical group Hemogenyx Pharmaceuticals announced on Wednesday that its wholly-owned subsidiary Immugenyx has entered into a research agreement with a global pharmaceutical company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.